EUVIMEDEUVIMED entdecken
Crossref

Four‐year drug survival of apremilast in patients with psoriasis

Megumi Kishimoto iD, Mayumi Komine iD, Koji Kamiya iD, Junichi Sugai, Aya Kuwahara, Mamitaro Ohtsuki

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Megumi Kishimoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Jichi Medical University, Tochigi, Japan. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Psoriasis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This real‐world study at a single academic center retrospectively examined the drug survival of apremilast for patients with psoriasis. Retrospective information was extracted from the medical records of patients with psoriasis treated with apremilast at the Department of Dermatology, Jichi Medical University Hospital, between March 1, 2017, and June 31, 2021. In total, 281 patients were included in this study. Of these patients, 22% had psoriatic arthritis and 57% had a history of prior systemic treatment, including biologics, before the initiation of apremilast. The 1‐, 2‐, 3‐, and 4‐year drug survival rates were 54%, 41%, 32%, and 30%, respectively. Cox regression analysis revealed that sex, duration of plaque psoriasis (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticPsoriasisHumansRetrospective StudiesAnti-Inflammatory Agents, Non-SteroidalSeverity of Illness IndexTreatment OutcomeThalidomide

Stichwörter der Autor:innen

Kaplan-Meier survival curvesadverse drug eventsapremilastpsoriasistreatment

Substanzen

Anti-Inflammatory Agents, Non-SteroidalapremilastThalidomide

Autor:innen und Institutionen

  • Department of Dermatology, Jichi Medical University, Tochigi, Japan.

ORCID-Profile: Megumi Kishimoto, Mayumi Komine, Koji Kamiya

Zitieren

APA

Kishimoto, M., Komine, M., Kamiya, K., Sugai, J., Kuwahara, A., & Ohtsuki, M. (2023). Four‐year drug survival of apremilast in patients with psoriasis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16766

Vancouver

Kishimoto M, Komine M, Kamiya K, Sugai J, Kuwahara A, Ohtsuki M. Four‐year drug survival of apremilast in patients with psoriasis. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16766

BibTeX
@article{Kishimoto2023,
  author = {Kishimoto, Megumi and Komine, Mayumi and Kamiya, Koji and Sugai, Junichi and Kuwahara, Aya and Ohtsuki, Mamitaro},
  title = {Four‐year drug survival of apremilast in patients with psoriasis},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16766}
}
Kostenlos starten →